Antiplatelet Drugs - Pharmacology

SECTION 1

Historical Context & Motivation

Arterial thrombosis — the pathological formation of platelet-rich clots within arteries — remains the leading cause of mortality worldwide, underpinning myocardial infarction, ischemic stroke, and peripheral arterial disease. For centuries, physicians understood that blood could clot dangerously within vessels, but the specific role of platelets in this process was not elucidated until the late nineteenth century. The discovery that small anucleate cell fragments derived from megakaryocytes orchestrate the initial hemostatic plug — and that this same process could become pathologically amplified — set the stage for pharmacologic intervention. The development of antiplatelet drugs represents one of the most impactful translational stories in cardiovascular medicine, transforming outcomes for millions of patients with atherosclerotic disease.

1897 • Synthesis of Aspirin

Felix Hoffmann at Bayer synthesized acetylsalicylic acid (aspirin), initially marketed as an analgesic and anti-inflammatory. Its antiplatelet properties would not be recognized for decades.

1967 • Aspirin's Antiplatelet Mechanism Unveiled

Harvey Weiss demonstrated that aspirin prolonged bleeding time by inhibiting platelet aggregation, and John Vane later identified irreversible cyclooxygenase (COX) inhibition as the mechanism — work that earned him the Nobel Prize in 1982.

1991 • Ticlopidine Approved

The first thienopyridine P2Y₁₂ receptor antagonist was approved, offering an alternative mechanism of platelet inhibition. Its use was limited by hematologic toxicity, spurring development of safer successors.

1998 • Clopidogrel & Abciximab Era

Clopidogrel (Plavix) gained FDA approval as a safer thienopyridine, and glycoprotein IIb/IIIa inhibitors such as abciximab revolutionized percutaneous coronary intervention (PCI).

2009–2015 • Next-Generation Agents

Prasugrel (2009), ticagrelor (2011), and vorapaxar (2014) introduced faster onset, more predictable pharmacokinetics, and novel targets (PAR-1), expanding the therapeutic arsenal for acute coronary syndromes.

The central clinical question that drove this pharmacologic evolution remains relevant today: How can we selectively inhibit pathological platelet aggregation in diseased arteries while preserving the hemostatic function needed to prevent bleeding? Understanding the mechanisms by which each drug class addresses this question is essential for rational prescribing and patient safety.

SECTION 2

Core Principles of Platelet Pharmacology

To understand how antiplatelet agents work, one must first appreciate the sequence of events that transforms circulating, quiescent platelets into an aggregated thrombus. Vascular injury exposes subendothelial collagen and von Willebrand factor (vWF), triggering platelet adhesion through glycoprotein Ib (GPIb) and glycoprotein VI (GPVI) receptors. Adherent platelets become activated, undergoing shape change and releasing the contents of their dense granules — adenosine diphosphate (ADP) and serotonin — as well as synthesizing thromboxane A₂ (TXA₂) from arachidonic acid. These autocrine and paracrine signals amplify platelet activation, culminating in conformational activation of the glycoprotein IIb/IIIa (GPIIb/IIIa) receptor, which cross-links platelets via fibrinogen bridges to form the definitive platelet plug.

Adhesion

Platelets bind to exposed collagen and vWF at the injury site via GPIb and GPVI receptors — the initial tethering step that anchors platelets to the vessel wall.

Activation & Amplification

Activated platelets release ADP and TXA₂, which act on P2Y₁₂ and TP receptors, respectively, to recruit and activate additional platelets in a positive-feedback loop.

Aggregation

GPIIb/IIIa receptors undergo conformational change to their high-affinity state, binding fibrinogen and vWF to cross-link adjacent platelets into a stable thrombus.

Pharmacologic Targets

Antiplatelet drugs intervene at distinct nodes: COX-1 (aspirin), P2Y₁₂ (clopidogrel, ticagrelor), GPIIb/IIIa (abciximab), phosphodiesterase (dipyridamole), and PAR-1 (vorapaxar).

✦

KEY TAKEAWAY

Think of platelet activation like a fire alarm system in a building. The initial injury is the smoke detector going off (adhesion). The alarm then triggers sprinklers and alerts neighboring zones (amplification via ADP and TXA₂). Finally, firefighters link arms to form a human chain blocking the exits (GPIIb/IIIa–fibrinogen aggregation). Antiplatelet drugs work by silencing specific alarm signals or preventing the firefighters from linking arms, thereby reducing pathological clot formation while still allowing some degree of hemostatic response.

SECTION 3

Visual Map of Platelet Activation & Drug Targets

This diagram illustrates the major platelet activation pathways and the pharmacologic targets of each antiplatelet drug class. Aspirin blocks TXA₂ synthesis via COX-1 inhibition (left), P2Y₁₂ antagonists block ADP signaling (right), GPIIb/IIIa inhibitors prevent the final common pathway of aggregation (bottom), and vorapaxar blocks thrombin-mediated activation at PAR-1 (center).

As the diagram above shows, antiplatelet drugs intervene at multiple distinct nodes in the platelet activation cascade. This multi-target pharmacology is clinically important because it explains why dual antiplatelet therapy (DAPT) — typically aspirin combined with a P2Y₁₂ inhibitor — is more efficacious than monotherapy in acute coronary syndromes. By blocking two independent amplification pathways simultaneously, DAPT achieves greater suppression of pathological platelet aggregation. However, this synergy also increases bleeding risk, which necessitates careful patient selection and duration-of-therapy decisions.

SECTION 4

Mechanisms of Action In Depth

COX-1 Inhibition: Aspirin

Aspirin irreversibly acetylates a serine residue (Ser-530) in the active site of cyclooxygenase-1 (COX-1), preventing the conversion of arachidonic acid to prostaglandin H₂, the precursor of TXA₂. Because platelets are anucleate and cannot synthesize new COX-1, aspirin's inhibition lasts the entire platelet lifespan of approximately 7–10 days. Even low doses (75–100 mg daily) achieve near-complete suppression of platelet TXA₂ production. At higher doses, aspirin also inhibits COX-2 in endothelial cells, reducing prostacyclin (PGI₂) synthesis — a potentially counterproductive effect since PGI₂ is an endogenous inhibitor of platelet activation.

ASPIRIN MECHANISM

Arachidonic Acid —[COX-1]→ PGH₂ → TXA₂ ⊘ ASPIRIN blocks COX-1 irreversibly

PGH₂ = prostaglandin H₂; TXA₂ = thromboxane A₂. Aspirin acetylates Ser-530 of COX-1, permanently inactivating the enzyme. Duration of effect = platelet lifespan ≈ 7–10 days.

P2Y₁₂ Receptor Antagonists

The P2Y₁₂ receptor is a G_i-coupled receptor on platelets that binds ADP and amplifies activation by inhibiting adenylyl cyclase (lowering cAMP) and activating PI3K signaling. There are two pharmacologic subclasses: the thienopyridines (clopidogrel, prasugrel) are prodrugs requiring hepatic CYP450 bioactivation to form active metabolites that bind irreversibly to P2Y₁₂, while ticagrelor is a direct-acting, reversible allosteric antagonist of P2Y₁₂ that does not require metabolic activation. This distinction has profound clinical implications: ticagrelor achieves faster, more consistent platelet inhibition, while clopidogrel's efficacy is compromised in patients carrying CYP2C19 loss-of-function alleles (poor metabolizers).

GPIIb/IIIa Inhibitors

The glycoprotein IIb/IIIa receptor (integrin α_IIbβ₃) represents the final common pathway of platelet aggregation, as it is the receptor that binds fibrinogen to cross-link platelets. Three intravenous agents target this receptor: abciximab (a monoclonal antibody Fab fragment), eptifibatide (a cyclic peptide), and tirofiban (a non-peptide mimetic). These agents are reserved primarily for high-risk percutaneous coronary interventions because of their potent aggregation blockade and associated bleeding risk.

Other Antiplatelet Mechanisms

Dipyridamole inhibits phosphodiesterase (PDE) and blocks adenosine reuptake, raising intracellular cAMP and cGMP levels in platelets. Elevated cyclic nucleotides inhibit platelet activation and promote vasodilation. Dipyridamole is often combined with low-dose aspirin for secondary stroke prevention. Vorapaxar is a first-in-class protease-activated receptor-1 (PAR-1) antagonist that blocks thrombin-mediated platelet activation. Because thrombin is one of the most potent platelet agonists, vorapaxar adds a complementary layer of inhibition but carries significant bleeding risk, particularly intracranial hemorrhage, and is contraindicated in patients with prior stroke or TIA.

⚠

Clinical Pearl: CYP2C19 Pharmacogenomics

Approximately 2–15% of patients (higher in East Asian populations) are CYP2C19 poor metabolizers, resulting in inadequate conversion of clopidogrel to its active metabolite. The FDA issued a boxed warning recommending consideration of alternative agents (prasugrel, ticagrelor) in these patients. Pharmacogenomic testing before initiating clopidogrel is increasingly incorporated into clinical decision-making.

SECTION 5

Classification & Comparative Pharmacology

Antiplatelet drugs can be systematically classified by their molecular target, binding characteristics (reversible vs. irreversible), route of administration, and need for metabolic activation. The following table provides a comprehensive comparison of the major agents used in clinical practice, highlighting features that drive therapeutic decision-making in acute coronary syndromes, stroke prevention, and peripheral arterial disease.

Drug	Target	Binding	Route	Prodrug?	Key Feature
Aspirin	COX-1	Irreversible	Oral	No	Cornerstone of DAPT; low cost
Clopidogrel	P2Y₁₂	Irreversible	Oral	Yes (CYP2C19)	Variable response; pharmacogenomic concern
Prasugrel	P2Y₁₂	Irreversible	Oral	Yes (esterase + CYP)	Faster onset; more consistent than clopidogrel
Ticagrelor	P2Y₁₂	Reversible	Oral	No	Direct-acting; BID dosing; dyspnea side effect
Abciximab	GPIIb/IIIa	Irreversible	IV	No	Monoclonal Ab fragment; used in PCI
Eptifibatide	GPIIb/IIIa	Reversible	IV	No	Cyclic peptide; short half-life
Dipyridamole	PDE / adenosine reuptake	Reversible	Oral	No	Used with aspirin for stroke prevention
Vorapaxar	PAR-1	Reversible (long t₁/₂)	Oral	No	Anti-thrombin axis; CI in prior stroke

Comparative pharmacology of major antiplatelet agents

Classification tree of antiplatelet drugs organized by molecular target (COX-1, P2Y₁₂, GPIIb/IIIa, PDE, and PAR-1), with binding reversibility and clinical context annotations. Note how agents within the P2Y₁₂ class diverge in their pharmacokinetic properties based on whether they are irreversible prodrugs or reversible direct-acting agents.

SECTION 6

Worked Example: Selecting Antiplatelet Therapy Post-PCI

A 62-year-old male presents with ST-elevation myocardial infarction (STEMI) and undergoes primary PCI with drug-eluting stent (DES) placement in the left anterior descending artery. He has no history of stroke or TIA. Pharmacogenomic testing reveals he is a CYP2C19 poor metabolizer (*2/*2 genotype). The clinical team must select an appropriate antiplatelet regimen.

Antiplatelet Selection: STEMI Post-PCI with CYP2C19 Poor Metabolizer Status

1
Step 1 — Identify the Clinical Indication

The patient has undergone primary PCI with DES placement for STEMI. This is a high-risk scenario for stent thrombosis if antiplatelet therapy is inadequate. Guidelines universally recommend dual antiplatelet therapy (DAPT) — aspirin plus a P2Y₁₂ inhibitor — for at least 12 months after DES implantation in ACS.

Indication: DAPT with aspirin + P2Y₁₂ inhibitor × 12 months
2
Step 2 — Consider Pharmacogenomic Data

The CYP2C19 *2/*2 genotype classifies this patient as a poor metabolizer. Clopidogrel requires CYP2C19-mediated bioactivation, and poor metabolizers generate insufficient active metabolite, leading to inadequate platelet inhibition and increased risk of thrombotic events, including stent thrombosis. The FDA boxed warning on clopidogrel specifically addresses this issue.

Clopidogrel is contraindicated in this patient due to CYP2C19 poor metabolizer status.
3
Step 3 — Evaluate Alternative P2Y₁₂ Inhibitors

Two alternatives are available: prasugrel (irreversible, prodrug with less CYP2C19 dependence) and ticagrelor (reversible, direct-acting, no CYP2C19 dependence). Both provide more potent and predictable platelet inhibition. Prasugrel is contraindicated in patients with prior stroke/TIA, age ≥75, or body weight <60 kg. This patient has none of these contraindications. Ticagrelor may cause dyspnea and requires BID dosing, which can impact adherence.

Both prasugrel and ticagrelor are viable; neither has a pharmacogenomic barrier in this patient.
4
Step 4 — Select the Regimen

Based on the TRITON-TIMI 38 trial (prasugrel vs. clopidogrel in ACS-PCI) and the PLATO trial (ticagrelor vs. clopidogrel in ACS), both agents demonstrated superior efficacy to clopidogrel. In this STEMI-PCI patient with no contraindications, either is appropriate. The team selects ticagrelor 90 mg BID plus low-dose aspirin 81 mg daily, based on ticagrelor's additional mortality benefit observed in PLATO.

Final regimen: Aspirin 81 mg PO daily + Ticagrelor 90 mg PO BID × 12 months
5
Step 5 — Counsel on Adherence and Monitoring

The patient is counseled that premature discontinuation of DAPT significantly increases stent thrombosis risk. Common side effects of ticagrelor — dyspnea and bradycardia — are discussed. The patient is instructed to avoid concurrent use of aspirin doses >100 mg (which may reduce ticagrelor's efficacy per the PLATO analysis) and to notify providers before any surgical procedures requiring DAPT interruption.

Patient education on adherence, side effects, and preoperative management is essential for therapeutic success.

SECTION 7

Strengths, Limitations & Adverse Effects

Each antiplatelet drug class offers distinct clinical advantages balanced against specific risks. The overarching tradeoff in antiplatelet pharmacology is efficacy in preventing thrombosis versus increased hemorrhagic risk. Understanding the adverse effect profiles, drug interactions, and clinical limitations of each class is critical for safe prescribing.

Drug Class	Strengths	Limitations / Adverse Effects
Aspirin (COX-1)	Inexpensive, extensive evidence base, once-daily dosing, reduces MI and stroke in secondary prevention, irreversible effect ensures sustained action.	GI bleeding and peptic ulceration (dose-dependent), aspirin hypersensitivity/allergy, Reye syndrome risk in children, limited benefit in low-risk primary prevention per recent trials (ARRIVE, ASPREE).
Thienopyridines (P2Y₁₂)	Effective as component of DAPT; prasugrel offers faster, more potent platelet inhibition; clopidogrel is generic and affordable.	Clopidogrel: CYP2C19-dependent response variability, slow onset. Prasugrel: higher bleeding risk, contraindicated in prior stroke/TIA, age ≥75, weight <60 kg. Ticlopidine (obsolete): TTP and neutropenia.
Ticagrelor (P2Y₁₂)	Direct-acting, no prodrug conversion needed, faster onset and offset than clopidogrel, mortality benefit in PLATO, reversible binding allows faster recovery if surgery needed.	Dyspnea (adenosine-mediated, ~14%), bradycardia, BID dosing reduces adherence, higher cost, must limit concurrent aspirin to ≤100 mg.
GPIIb/IIIa Inhibitors	Most potent antiplatelet effect (blocks final common pathway), rapid onset IV, useful as rescue therapy in PCI complications.	Significant bleeding risk, thrombocytopenia (especially abciximab), IV-only administration limits chronic use, largely supplanted by potent oral P2Y₁₂ inhibitors.
Vorapaxar (PAR-1)	Novel mechanism targeting thrombin-mediated activation, additive benefit atop standard DAPT in post-MI patients without stroke history.	Significant intracranial hemorrhage risk, extremely long half-life (~8 days) makes bleeding difficult to manage, contraindicated in prior stroke/TIA, limited clinical adoption.

Comparison of antiplatelet drug strengths and limitations

✦

KEY TAKEAWAY

Selecting an antiplatelet regimen is analogous to calibrating a thermostat in a precision lab: too little inhibition and the system 'overheats' with thrombosis; too much and it 'freezes' with uncontrolled bleeding. The clinician must consider the patient's thrombotic risk (stent type, ACS presentation, comorbidities) against their bleeding risk (age, renal function, concomitant anticoagulants, history of GI bleeding) to find the optimal 'temperature setting.'

SECTION 8

Connections to Advanced Antithrombotic Therapy

Antiplatelet drugs represent one arm of the broader antithrombotic pharmacologic strategy. While they primarily target arterial (platelet-rich, 'white') thrombi, anticoagulants (heparin, warfarin, direct oral anticoagulants) primarily target the coagulation cascade responsible for venous (fibrin-rich, 'red') thrombi. In clinical practice, the distinction is not absolute — patients with atrial fibrillation and concomitant coronary stents may require triple antithrombotic therapy (aspirin + P2Y₁₂ inhibitor + an anticoagulant), which dramatically increases bleeding risk and necessitates careful duration optimization.

Feature	Antiplatelet Drugs	Anticoagulants
Primary Target	Platelet activation & aggregation	Coagulation cascade (thrombin, Factor Xa)
Thrombus Type	Arterial (white thrombus, platelet-rich)	Venous (red thrombus, fibrin-rich)
Key Indications	ACS, PCI/stents, secondary stroke prevention, PAD	DVT, PE, atrial fibrillation, mechanical heart valves
Monitoring	Platelet function assays (VerifyNow, TEG); rarely used routinely	INR (warfarin), anti-Xa levels (heparin/LMWH), aPTT
Reversal	Platelet transfusion (limited efficacy for irreversible agents), desmopressin	Vitamin K (warfarin), protamine (heparin), idarucizumab (dabigatran), andexanet alfa (Xa inhibitors)
Emerging Overlap	Low-dose rivaroxaban (2.5 mg BID) added to DAPT in COMPASS trial for 'dual pathway inhibition'	DOACs replacing warfarin for most indications; role expanding in cancer-associated thrombosis

Antiplatelet drugs vs. anticoagulants: a comparative framework

Looking forward, the field of antiplatelet pharmacology is evolving in several exciting directions. The concept of de-escalation strategies — switching from potent agents (ticagrelor/prasugrel) to clopidogrel after the highest-risk period — is supported by trials like TWILIGHT and TOPIC, aiming to maintain efficacy while reducing bleeding. Simultaneously, platelet function testing-guided therapy and pharmacogenomics are inching toward personalized antiplatelet regimens, though their routine implementation remains debated. Understanding the fundamental pharmacology covered in this lesson provides the foundation for engaging with these advanced clinical questions.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Aspirin irreversibly inhibits COX-1 in platelets, yet its clinical antiplatelet effect lasts approximately 7–10 days despite the drug's plasma half-life of only 15–20 minutes. Explain why the duration of antiplatelet effect so greatly exceeds the drug's plasma half-life.

Show answer

Aspirin's antiplatelet effect outlasts its plasma presence because it irreversibly acetylates COX-1 — once the enzyme is inactivated, it cannot be regenerated. Platelets are anucleate cells that lack the nuclear machinery to synthesize new proteins, including COX-1. Therefore, aspirin's inhibitory effect persists for the remaining lifespan of each affected platelet, which is approximately 7–10 days. New platelet production from megakaryocytes in the bone marrow gradually restores the pool of uninhibited platelets, which is why approximately 10% of the platelet pool is replaced daily and clinically meaningful recovery of aggregation occurs after 5–7 days of aspirin discontinuation.

Question 2: BASIC CALCULATION

If approximately 10% of the circulating platelet pool is replaced daily by new megakaryocyte-derived platelets, and a patient takes aspirin 81 mg daily (achieving near-complete COX-1 inhibition each day), what approximate percentage of circulating platelets will have uninhibited COX-1 at any given time under steady-state dosing? What happens if the patient misses 3 consecutive doses?

Show answer

Under steady-state daily dosing, each day's dose inhibits the newly produced platelets (approximately 10% of the pool). Therefore, at any given time, essentially 0% of platelets have functional COX-1 because the daily aspirin dose recaptures newly released platelets before they can contribute meaningful TXA₂ production. If the patient misses 3 consecutive doses, approximately 30% of the circulating pool will consist of new, uninhibited platelets (3 days × 10%/day). This fraction can generate sufficient TXA₂ to partially restore platelet aggregation, which is clinically significant and explains why even brief lapses in aspirin adherence can increase thrombotic risk, particularly in post-stent patients.

Question 3: INTERMEDIATE

A patient with non-ST-elevation ACS is started on DAPT with aspirin and clopidogrel. Platelet function testing at 48 hours shows a P2Y₁₂ reaction unit (PRU) value of 280 (therapeutic target <208 PRU). Pharmacogenomic results return showing CYP2C19 *1/*2 (intermediate metabolizer). The patient has no history of stroke. What pharmacologic adjustment is most appropriate, and why?

Show answer

The elevated PRU of 280 indicates inadequate platelet inhibition despite clopidogrel loading, which is consistent with the CYP2C19 *1/*2 intermediate metabolizer genotype. This patient generates suboptimal levels of clopidogrel's active metabolite. The most appropriate adjustment is to switch to either ticagrelor (180 mg loading, then 90 mg BID) or prasugrel (60 mg loading, then 10 mg daily). Since the patient has no history of stroke/TIA and no other contraindications listed, either agent is acceptable. Ticagrelor is often preferred because its reversible, direct-acting mechanism provides predictable pharmacodynamics independent of CYP2C19 genotype. Simply increasing the clopidogrel dose has not been reliably shown to overcome genetic resistance in prospective trials.

Question 4: APPLIED

A 70-year-old woman with a history of STEMI (treated with DES 8 months ago, currently on aspirin + ticagrelor) is now diagnosed with atrial fibrillation with a CHA₂DS₂-VASc score of 4. Her cardiologist wants to add apixaban for stroke prevention. Discuss the pharmacologic rationale, risks, and evidence-based strategies for managing this patient's antithrombotic regimen.

Show answer

This patient requires both antiplatelet therapy (for stent protection) and anticoagulation (for atrial fibrillation stroke prevention), creating a scenario of triple antithrombotic therapy. The combination of aspirin + P2Y₁₂ inhibitor + DOAC dramatically increases bleeding risk. Evidence from the AUGUSTUS, RE-DUAL PCI, and ENTRUST-AF PCI trials supports dropping aspirin early (within 1–4 weeks of PCI) and continuing dual therapy with a P2Y₁₂ inhibitor plus DOAC to reduce bleeding while maintaining acceptable thrombotic protection. Since this patient is 8 months post-DES (past the highest stent thrombosis risk window), the recommended strategy would be to discontinue aspirin, continue clopidogrel (preferred over ticagrelor in this context due to lower bleeding when combined with a DOAC), and initiate apixaban at either full dose (5 mg BID) or reduced dose if meeting criteria. The total duration of dual antithrombotic therapy should extend to 12 months post-PCI, after which anticoagulation alone may suffice.

Question 5: CRITICAL THINKING

Ticagrelor, unlike clopidogrel, is a reversible P2Y₁₂ antagonist, yet the ACC/AHA guidelines recommend discontinuing ticagrelor at least 5 days before elective CABG surgery — the same washout period as for the irreversible agent clopidogrel. Propose a pharmacologic explanation for why the recommended preoperative hold times are similar despite the fundamental difference in receptor binding kinetics, and discuss whether you believe the guideline is optimally evidence-based.

Show answer

At first glance, one might expect ticagrelor's reversible binding to allow faster recovery of platelet function compared to clopidogrel's irreversible inhibition. However, several pharmacologic factors equalize the clinical washout period. First, ticagrelor (and its active metabolite AR-C124910XX) achieves very high receptor occupancy at therapeutic doses, and despite reversibility, dissociation requires sufficient time for plasma drug levels to decline. Ticagrelor's elimination half-life is approximately 7–9 hours, meaning approximately 5 half-lives (35–45 hours) are needed for near-complete clearance — suggesting a theoretical 2–3 day recovery. In contrast, clopidogrel's active metabolite has a short half-life but irreversibly modifies platelets, requiring new platelet synthesis for recovery. The 5-day recommendation for clopidogrel reflects ~50% platelet pool turnover. The similar guideline for ticagrelor likely reflects a conservative approach driven by limited surgical trial data, inter-patient variability in ticagrelor metabolism, and the contribution of the long-lived active metabolite. Platelet function studies suggest that ticagrelor's antiplatelet effect resolves 2–3 days faster than clopidogrel's in many patients, and emerging data from RAPID CABG and similar trials support shorter washout periods (2–3 days) for ticagrelor. This is an area where guidelines may be overly conservative and could benefit from platelet function testing-guided timing in individual patients.

SUMMARY

Antiplatelet Drugs — Key Concepts Review

Summary

Antiplatelet drugs prevent arterial thrombosis by inhibiting distinct steps of platelet activation and aggregation. Aspirin irreversibly inhibits COX-1, blocking TXA₂ synthesis for the platelet's entire 7–10 day lifespan. P2Y₁₂ receptor antagonists — including the prodrugs clopidogrel and prasugrel, and the direct-acting reversible agent ticagrelor — block ADP-mediated platelet amplification and form the second pillar of dual antiplatelet therapy (DAPT). GPIIb/IIIa inhibitors (abciximab, eptifibatide, tirofiban) block the final common pathway of fibrinogen cross-linking and are used intravenously during high-risk PCI.

Clinical decision-making in antiplatelet therapy requires balancing thrombotic risk against bleeding risk, informed by patient-specific factors such as CYP2C19 pharmacogenomic status, history of stroke, age, and concomitant antithrombotic therapy. Additional agents including dipyridamole (PDE inhibition, stroke prevention) and vorapaxar (PAR-1 antagonism) expand the therapeutic toolkit. The distinction between antiplatelet drugs targeting arterial thrombi and anticoagulants targeting venous thrombi, along with evolving strategies of de-escalation and dual pathway inhibition, represents the cutting edge of antithrombotic pharmacology.